drugset / Trial / NCT01536587

Effects of Salmeterol on Autonomic Nervous System

NCT01536587

Phase 4 Completed 32 enrolled GlaxoSmithKline
NaSingle-groupSingle-blindTreatment

Summary

This is a 4-week non-randomized, partially blinded, single-arm monocentre study in subjects with Chronic Obstructive Pulmonary Disease (COPD) Global Initiative for Chronic Obstructive Lung Disease (GOLD) class II or III with the aim to demonstrate that inhaled therapy with salmeterol reduces sympathetic activity as evaluated by microneurography. A maximum of 32 subjects is planned to be enrolled.

Timeline

Start
2012-07
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Salmeterol Other / unclassified 50 ug Inhaled